logo
Biotech company prepares to begin operating from new Chehalis location

Biotech company prepares to begin operating from new Chehalis location

Yahoo20-07-2025
Jul. 18—Northwest Control Systems, LLC, is nearly set to open up shop from its new location in Chehalis at 582 S. Market Blvd.
The company, which currently operates in Rochester, purchased the building in May and is about a month away from completing renovations.
Northwest Control Systems, led by CEO Roger McIntosh and Business Director and General Manager Gulnur Tuyenbayeva, started over two years ago from its parent company MAS and aims to serve the laboratory community with high quality and innovative fluid handling and automation solutions. It specializes in automation for laboratories, factories and industrial processes, offering products such as controller boards, reader assemblies, pressure sensors, as well as materials used for research purposes.
"It's a broad variety of components used primarily for automating different industrial processes," McIntosh said. "And, up until now, it's focused very much on biotech applications, like instruments that are used for analysis of biological samples."
McIntosh and Tuyenbayeva have mostly been operating as a two-person unit and have been searching for a new facility for over a year, and they made offers on 16 different properties in the Lewis County area before landing on the South Market Boulevard property. They hope the 2,400-square foot building will expand not only their operations but their staffing, as McIntosh stated that the company is looking to hire one to two employees with experience and knowledge in science, technology and/or engineering.
"One of the things that we need very soon is we would like to hire up to two employees. Operating from someplace 20 to 30 miles out in the country is not ideal for attracting the type of employees that we want," McIntosh said of the decision to relocate to Chehalis. "One of the key components is that we have a good layout within the building so we can have a nice conference room to work with clients and we have enough room to do the limited type of manufacturing and testing that we do on our components."
McIntosh said the building, which was built in 1935 and previously housed a company that published a logging newspaper, was in good condition upon purchase but needed a few renovations, including a new roof, exterior and interior painting, new flooring, paving for the parking area, and more.
Northwest Control Systems is beginning a new project in the near future in which it will convert waste biomass to purified chemicals and energy, McIntosh said. This succeeds another recent innovation by the company that isolates single cells from tissue samples, enabling DNA sequencing at the cell level to help identify specific mutations in cancer cells.
"It's a very interesting process that the customer has developed to automate the process of taking waste organic material and loading it into an oven," McIntosh said. "Then it's a surprisingly complex process where you have to very precisely adjust the mixture of various gasses within this oven and monitor the output of the materials. Ultimately, you're taking waste biomass and producing high volume chemicals and energy. We'll definitely need additional employee help for that."
McIntosh said the company is expanding to also serve the factory automation market. In addition to biotech, he has been involved in this market over the years as well.
"Some of the components and some of the operations are not so different between automating factory and automating laboratory operations. We're intending to locate companies within the general area, and it could be as far away as Olympia, Tacoma, Seattle, Spokane," McIntosh said. "We've got a company in Spokane we're working with now to help automate industrial processes as well as laboratory processes."
Additionally, Northwest Control Systems has dabbled in artificial intelligence. McIntosh said one AI-based product the company has been working on is close to coming to market.
"It's an AI-based software product to essentially create automation scripts for laboratories and could be for factories, as well," he said. "It actually saves a tremendous amount of time. It cuts the overall development time for a system like that probably in half. It's definitely a big advancement and something that we've been involved in for a while."
To learn more about Northwest Control Systems and its products, visit northwestcontrolsystems.com.
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

A Divided Fed Eyes Future Rate Cuts but Won't Move This Week
A Divided Fed Eyes Future Rate Cuts but Won't Move This Week

Wall Street Journal

time22 minutes ago

  • Wall Street Journal

A Divided Fed Eyes Future Rate Cuts but Won't Move This Week

Federal Reserve officials expect they will need to resume lowering interest rates eventually—they just aren't ready to do so Wednesday. The questions dividing them center on what evidence they need to see first, and whether waiting for that clarity turns out to be a mistake. The central bank had a united front when officials paused rate cuts earlier this year after President Trump's tariffs raised fears of renewed inflation. But with tariff-related price increases proving milder than many feared and signs that hiring may be softening, officials on the rate-setting committee are now fractured into roughly three camps over whether to resume easing.

Pro-regulatory advocates eye civil suits to fill Trump admin gaps
Pro-regulatory advocates eye civil suits to fill Trump admin gaps

E&E News

time39 minutes ago

  • E&E News

Pro-regulatory advocates eye civil suits to fill Trump admin gaps

Access to civil lawsuits could offer a key option for vulnerable communities as EPA shrinks its regulatory power, according to a report released Monday by a pro-regulatory group. Environmental and public health lawsuits, often filed by private citizens, will be instrumental in generating financial justice and industry transparency through the coming years of the Trump administration, said the report from the Center for Progressive Reform, a nonprofit research organization. Since President Donald Trump took office, environmentalists have been shaken by EPA plans for regulatory rollbacks, staffing cuts and a more pro-industry approach. Earlier this month, the agency announced it would reorganize and eliminate its Office of Research and Development, firing or reassigning hundreds of employees. Advertisement The Center for Progressive Reform in its report argues that a weakened EPA will create gaps in research and regulatory protection, which can be filled by civil suits.

Biotech stocks dip as Trump administration mulls patent fee overhaul
Biotech stocks dip as Trump administration mulls patent fee overhaul

Yahoo

time40 minutes ago

  • Yahoo

Biotech stocks dip as Trump administration mulls patent fee overhaul

-- Biotech stocks fell across the board Monday afternoon, with the SPDR S&P Biotech ETF (NYSE:XBI) dropping to a low of 1.1% after reports emerged that the Trump administration is considering a major overhaul of the U.S. patent system. According to The Wall Street Journal, Commerce Department officials are discussing a plan to charge patent holders between 1% and 5% of their overall patent value. This potential change, being considered by Commerce Secretary Howard Lutnick as part of efforts to raise revenue and reduce the government's budget deficit, could generate tens of billions of dollars. The proposed fee structure would represent a fundamental shift in the 235-year-old patent system, which currently requires patent holders to pay relatively modest flat fees totaling up to approximately $10,000 over multiple years. Under the new system, these costs would increase dramatically for many patent holders, functioning essentially as a property tax on intellectual property. This potential change could have significant implications for biotech companies, which rely heavily on patent protection for their drug developments and innovations. The pharmaceutical and biotechnology sectors typically maintain extensive patent portfolios to protect their research investments and ensure market exclusivity for their products. The news particularly affected major players in the biotech space, with companies like Pfizer (NYSE:PFE) trading lower during Monday's session as investors assessed the potential impact of higher patent-related costs on future profitability. Related articles Biotech stocks dip as Trump administration mulls patent fee overhaul Apollo economist warns: AI bubble now bigger than 1990s tech mania If Powell goes, does Fed trust go with him? Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store